Drug data last refreshed 4h ago
FREAMINE III 10% is an injectable amino acid formulation indicated for muscle atrophy and muscle loss, primarily used in parenteral nutrition support. It provides essential and non-essential amino acids to maintain or restore muscle protein synthesis in patients unable to meet nutritional needs orally. The product works by supplying exogenous amino acids for protein anabolism and metabolic support.
LOE-approaching status signals declining growth trajectory; brand teams are typically focused on maintaining market share and managing transition planning rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
The Glucagonotropic Effect of Amino Acids in Humans
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Bioavailability of Plant Protein Amino Acids
Worked on FREAMINE III 10% at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moRoles on FREAMINE III 10% are primarily commercial and operational, focused on defending market share in hospital and health system channels against entrenched competitors. Career growth is limited; positions are stable but offer modest advancement opportunity given the LOE-approaching lifecycle and commodity-market dynamics.